leadf
logo-loader
viewAmryt Pharma PLC

Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results.

The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide.

Wiley talks through these results which show 19% YoY revenue growth in the quarter to $49.3m, with a rise in full year revenue guidance to $180m - $182m.

Quick facts: Amryt Pharma PLC

Price: 195 GBX

AIM:AMYT
Market: AIM
Market Cap: £348.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma raises $40M in private placement from new and existing...

Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies. Wiley says investors include Stonepine...

on 9/12/20

2 min read